India May Soon Allow Outside Phase I Drug Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
Certain studies by multinational drug companies would be allowable under pending changes to India’s clinical trial regulations.
You may also be interested in...
Booming Clinical Research Business Could Trigger Regulatory Overhaul In India
SAN FRANCISCO - Foreign companies could soon get the go-ahead to conduct Phase I studies in India, as part of a national regulatory overhaul spurred on by booming clinical research business, regional experts say
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.